Welcome to our dedicated page for Salarius Pharmaceuticals SEC filings (Ticker: SLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking seclidemstat trial costs or SP-3164 development milestones inside a 300-page report isn’t easy. Anyone searching for “Salarius Pharmaceuticals SEC filings explained simply” or wondering how to read a “Salarius Pharmaceuticals annual report 10-K simplified” is really asking for clarity behind the science-heavy disclosures. Stock Titan delivers that clarity.
Every document hits our feed the moment it’s posted to EDGAR—whether it’s a “Salarius Pharmaceuticals quarterly earnings report 10-Q filing”, an unexpected “Salarius Pharmaceuticals 8-K material events explained” alert on a licensing deal, or the “Salarius Pharmaceuticals insider trading Form 4 transactions” that hint at management’s confidence. Our AI-powered summaries translate technical language into plain English, flagging R&D expense tables, cash-runway metrics and milestone-payment clauses. You’ll even see a dedicated stream for “Salarius Pharmaceuticals Form 4 insider transactions real-time” alongside color-coded charts that make a “Salarius Pharmaceuticals earnings report filing analysis” effortless.
Ready to start understanding Salarius Pharmaceuticals SEC documents with AI? With comprehensive coverage of everything from the “Salarius Pharmaceuticals proxy statement executive compensation” to shelf registrations for future capital raises, you can:
- Monitor “Salarius Pharmaceuticals executive stock transactions Form 4” before pivotal readouts
- Compare quarter-over-quarter burn rates without manual number-crunching
- Stay ahead of clinical-trial announcements and collaboration disclosures
All filings update in real time, and expert commentary spotlights the sections that matter most to oncology-focused investors—so you spend minutes, not hours, decoding complex biotech documents.
Salarius Pharmaceuticals (SLRX) filed Amendment No. 7 to its S-1 for a primary offering of 1,960,784 shares of common stock (or pre-funded warrants in lieu of shares) together with Series A warrants for up to 1,960,784 shares and Series B warrants for up to 1,960,784 shares. The filing also covers representative warrants for up to 98,039 shares and up to 5,980,391 shares issuable upon exercise of the pre-funded and common warrants. The assumed combined public offering price is $4.08 per share and accompanying warrants.
The common warrants are exercisable upon issuance; Series A expire in five years and Series B in one year. Pre-funded warrants carry a $0.0001 exercise price and are offered to maintain 4.99% (or 9.99%) ownership limits. Underwriters have a 45‑day option to purchase up to 294,118 additional shares and/or warrants.
The offering is tied to Salarius’ planned merger with Decoy Therapeutics. Based on an assumed price of $4.08 and the merger exchange mechanics, legacy Salarius holders would own ~14.8% and Decoy holders ~85.2% of the company before this offering’s dilution. Preferred stock issued at closing includes price protection down to a $3.75 floor, with an initial reference price of $10.50. As of October 14, 2025, Salarius estimated $4.3 million in cash and cash equivalents, and it has regained Nasdaq compliance with bid price and equity standards.
Salarius Pharmaceuticals (SLRX) approved a transaction bonus for its Acting CEO, EVP & CFO, Mark J. Rosenblum. The Board authorized a $225,000 cash bonus, payable following the closing of the transactions contemplated by the Merger Agreement with Decoy Therapeutics.
Payment requires Mr. Rosenblum’s continued employment through the Closing Date and will be paid at or before the next payroll date after closing.
Salarius Pharmaceuticals (SLRX) announced it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), as confirmed by a Nasdaq Hearings Panel on October 10, 2025.
Nasdaq placed the company under a one-year Mandatory Panel Monitor starting October 10, 2025. If Salarius falls out of compliance with the equity standard during this monitoring period, Nasdaq staff will issue a delisting determination without allowing a compliance plan or cure period; Salarius would retain the right to request a hearing.
On October 13, 2025, the company issued a press release reiterating its compliance status.
Salarius Pharmaceuticals, Inc. reports that since
The company is awaiting Nasdaq's confirmation of compliance with the Exchange's Equity Standard. The equity estimate is preliminary, unaudited and subject to change as quarter-end closing procedures are completed. The filing includes standard forward-looking cautionary language about risks, including the company's prior Nasdaq noncompliance.
Salarius Pharmaceuticals (SLRX) amended its S-1 to register a financing tied to a two-step merger with Decoy Therapeutics. The transaction contemplates issuance of newly designated Series A and Series B preferred stock to Decoy stockholders and certain Decoy noteholders, with conversion economics tied to an assumed offering price of $5.27 per share and a Qualified Financing minimum of $6.0 million. Amendment No. 1 fixed a prior exchange ratio such that Salarius legacy stockholders would retain approximately 14.1% and Decoy legacy stockholders 85.9% on a fully diluted basis, before additional financing dilution.
The filing discloses significant near-term risks: Nasdaq has sent delisting notices and a Hearings Panel granted extensions subject to milestones; investors would face immediate dilution (pro forma adjusted net tangible book value would be $1.45 per share versus the offering price of $5.27), there is no public market for the offered warrants, and conversion of the Preferred Stock is conditioned on Nasdaq initial listing approval and stockholder votes. The combined company will depend on additional financings and faces customary merger and clinical-development risks.
Salarius Pharmaceuticals amended its merger-related preferred stock terms on September 17, 2025 to change how conversion adjustments are calculated. The Fifth Amendment sets an Initial Issuance Price of $10.50 per share as the baseline for computing proportional conversion adjustments triggered by any dilutive subsequent financing, and it establishes a floor price of $3.75 per share as the lowest per-share price used in those price-protection calculations. The amendment also revises the Series B Preferred Stock redemption price to be the Initial Issuance Price multiplied by 1,000. Except for these modifications, the Merger Agreement remains in effect. The filing incorporates the full Fifth Amendment and the Certificates of Designations as exhibits.
Salarius Pharmaceuticals (SLRX) reported Nasdaq noncompliance and actions taken to avoid delisting. The company effected a 1-for-15 reverse stock split on August 15, 2025 to address a sub-$1.00 closing bid price and expects to regain compliance with Nasdaq's Minimum Bid Price Requirement by the August 29, 2025 deadline. Nasdaq previously issued a Delisting Notice for failure to meet the $1.00 minimum bid and separately for failure to meet the Equity Standard based on its 2024 results. Salarius appealed and the Hearings Panel granted extensions contingent on scheduled milestones, with Nasdaq later extending the equity-compliance and minimum-bid deadlines. The filing contains forward-looking statements about regaining compliance and associated risks.
Salarius Pharmaceuticals, Inc. filed a Current Report on Form 8-K dated August 22, 2025 noting that, in connection with a Prospectus Supplement, the company is submitting a legal opinion from Hogan Lovells US LLP concerning the validity of the shares being registered. That legal opinion is attached as Exhibit 5.1 and is incorporated by reference under Item 9.01 (Financial Statements and Exhibits).
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
